GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Scaled Net Operating Assets

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Scaled Net Operating Assets : 0.22 (As of Nov. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Algernon Pharmaceuticals's operating assets for the quarter that ended in Nov. 2023 was $2.83 Mil. Algernon Pharmaceuticals's operating liabilities for the quarter that ended in Nov. 2023 was $2.14 Mil. Algernon Pharmaceuticals's Total Assets for the quarter that ended in Aug. 2023 was $3.11 Mil. Therefore, Algernon Pharmaceuticals's scaled net operating assets (SNOA) for the quarter that ended in Nov. 2023 was 0.22.


Algernon Pharmaceuticals Scaled Net Operating Assets Historical Data

The historical data trend for Algernon Pharmaceuticals's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Scaled Net Operating Assets Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only 3.29 1.15 0.55 0.41 0.16

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.50 0.54 0.22 0.22

Competitive Comparison of Algernon Pharmaceuticals's Scaled Net Operating Assets

For the Biotechnology subindustry, Algernon Pharmaceuticals's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Scaled Net Operating Assets falls into.



Algernon Pharmaceuticals Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Algernon Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Aug. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Aug. 2023 )
=(Operating Assets (A: Aug. 2023 )-Operating Liabilities (A: Aug. 2023 ))/Total Assets (A: Aug. 2022 )
=(3.019-2.018)/6.303
=0.16

where

Operating Assets(A: Aug. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=3.112 - 0.093
=3.019

Operating Liabilities(A: Aug. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.018 - 0 - 0
=2.018

Algernon Pharmaceuticals's Scaled Net Operating Assets (SNOA) for the quarter that ended in Nov. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Nov. 2023 )
=(Operating Assets (Q: Nov. 2023 )-Operating Liabilities (Q: Nov. 2023 ))/Total Assets (Q: Aug. 2023 )
=(2.828-2.144)/3.112
=0.22

where

Operating Assets(Q: Nov. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=2.882 - 0.054
=2.828

Operating Liabilities(Q: Nov. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=2.144 - 0 - 0
=2.144

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Headlines

From GuruFocus

Algernon Pharmaceuticals Announces Launch of Rights Offering

By sperokesalga sperokesalga 03-21-2023

Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board

By Stock market mentor Stock market mentor 01-11-2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

By Stock market mentor Stock market mentor 01-17-2023